The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

BACKGROUND: Unresectable advanced or recurrent gastric cancer patients have a poor prognosis. PD-1 monotherapy regimen and PD-1 combined chemotherapy regimen have become the standard third- and first-line treatment for advanced gastric cancer, respectively. However, the status of immune checkpoint i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianzheng, He, Yunduan, Zhang, Baiwen, Lv, Huifang, Nie, Caiyun, Chen, Beibei, Xu, Weifeng, Zhao, Jing, Cheng, Xiaojiao, Li, Qingli, Tu, Shuiping, Chen, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198424/
https://www.ncbi.nlm.nih.gov/pubmed/35719979
http://dx.doi.org/10.3389/fonc.2022.924149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198424/
https://www.ncbi.nlm.nih.gov/pubmed/35719979
http://dx.doi.org/10.3389/fonc.2022.924149

Ejemplares similares